Home › Triple-Negative Breast Cancer › District of Columbia › Washington
Triple-Negative Breast Cancer clinical trials in Washington, DC
11 studies for Triple-Negative Breast Cancer are looking for participants at sites in and around Washington (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Collection of CSF Samples From Participants With Metastatic Triple Negative Breast Cancer (TNBC) and HER2+ Breast Cancer With no Prior History Nor Active Radiographically Detectable Brain Metastases
RecruitingObservational study
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
RecruitingPhase 3
- Washington Hospital Center ( Site 0098), Washington D.C.
- Holy Cross Hospital ( Site 0091), Silver Spring · 7 mi away
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
RecruitingPhase 3
- Holy Cross Hospital ( Site 0069), Silver Spring · 7 mi away
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
RecruitingPhase 1
- Georgetown University Medical Center, Washington D.C.
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
RecruitingPhase 3
- MedStar Georgetown University Hospital, Washington D.C.
- MedStar Washington Hospital Center, Washington D.C.
A Synthetic Lethality-Focused Algorithm to Identify Therapeutic Options in Advanced Metastatic Breast Cancer (SYNTHESIS-Breast)
Recruiting
- National Institutes of Health Clinical Center, Bethesda · 7 mi away
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
RecruitingPhase 1
- Normunity Investigational Site, Washington D.C.
Study of XB010 in Subjects With Solid Tumors
RecruitingPhase 1
- Georgetown University Medical Center, Washington D.C.
Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)
RecruitingPhase 2
- National Institute of Health Clinical Center, Bethesda · 7 mi away
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
RecruitingPhase 2
- Georgetown University Medical Center, Washington D.C.
CtDNA Based MRD Testing for NAC Monitoring in TNBC
RecruitingObservational study
- George Washington University, Washington D.C.
Triple-Negative Breast Cancer trials in other cities
- Houston, TX42 studies
- New York City, NY31 studies
- Nashville, TN28 studies
- Los Angeles, CA27 studies
- Boston, MA26 studies
- San Antonio, TX23 studies
- St. Louis, MO21 studies
- Arlington, VA20 studies
- Atlanta, GA20 studies
- Dallas, TX18 studies
- Chicago, IL16 studies
- Columbus, OH16 studies
Other studies in Washington
- Cancer (all types)58 studies
- Non-Small Cell Lung Cancer55 studies
- Breast Cancer46 studies
- Metastatic Cancer43 studies
- Lung Cancer41 studies
- Prostate Cancer38 studies
- Obesity33 studies
- Colorectal Cancer29 studies
- Cardiovascular Disease28 studies
- Bladder Cancer26 studies
- Acute Myeloid Leukemia24 studies
- Ovarian Cancer23 studies
From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.